In this study, the immunoadjuvant effects of recombinant porcine interferon alpha (rPoIFNα) on the killed virus vaccine (KV) of porcine reproductive and respiratory syndrome virus (PRRSV) in pigs were investigated. The experimental pigs were divided into six groups, including normal control group, rPoIFNα control group, PRRSV KV control group, KV+40,000 U rPoIFNα immunization group, KV+400,000 U rPoIFNα immunization group, and KV+4,000,000 U rPoIFNα immunization group. The experimental pigs were boosted immunized on the 28th day after the initial immunization, and the heparinized blood and serum samples were collected at different time points of these two immunizations to detect and evaluate the immune responses of pigs after immunization by ELISA assay, neutralization assay, flow cytometry, and so on. The results showed that the proportion of the levels of PRRSV-specific antibodies, neutralizing antibodies, stimulation index, IL-4, IFN-γ, and lymphocytes within the groups immunized with KV+rPoIFNα were significantly higher than that group immunized with KV alone. The humoral and cellular immune responses in pigs were markedly enhanced by rPoIFNα after the coadministration with KV vaccine. Therefore, we tentatively think that rPoIFNα is a potential immune promoter with prospects for future applications in the pig industry.
Get full access to this article
View all access options for this article.
References
1.
Bassaganya-RieraJ, ThackerBJ, YuS, et al.Impact of immunizations with porcine reproductive and respiratory syndrome virus on lymphoproliferative recall responses of CD8+ T cells. Viral Immunol, 2004; 17:25–37.
2.
CanelliE, CatellaA, BorghettiP, et al.Efficacy of a modified-live virus vaccine in pigs experimentally infected with a highly pathogenic porcine reproductive and respiratory syndrome virus type 1 (HP-PRRSV-1). Vet Microbiol, 2018; 226:89–96.
3.
CepicaA, and DerbyshireJB. The role of interferon in spontaneous cell-mediated cytotoxicity in pigs. Vet Microbiol, 1986; 11:69–77.
4.
CharerntantanakulW. Adjuvants for porcine reproductive and respiratory syndrome virus vaccines. Vet Immunol Immunopathol, 2009; 129:1–13.
5.
CharerntantanakulW, PlattR, JohnsonW, et al.Immune responses and protection by vaccine and various vaccine adjuvant candidates to virulent porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol, 2006; 109:99–115.
6.
CullVS, BroomfieldS, BartlettEJ, et al.Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther, 2002; 9:1369–1378.
7.
de Avila BottonS, BrumMC, BautistaE, et al.Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine, 2006; 24:3446–3456.
8.
DenizotF, and LangR. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods, 1986; 89:271–277.
9.
DuY, QiJ, LuY, et al.Evaluation of a DNA vaccine candidate co-expressing GP3 and GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) with interferon alpha/gamma in immediate and long-lasting protection against HP-PRRSV challenge. Virus Genes, 2012; 45:474–487.
10.
DwivediV, ManickamC, BinjawadagiB, et al.PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs. Vet Microbiol, 2013; 166:47–58.
11.
HiremathJ, KangKI, XiaM, et al.Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs. PLoS One, 2016; 11:e0151922.
12.
JegoG, PaluckaAK, BlanckJP, et al.Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity, 2003; 19:225–234.
13.
JiangW, JiangP, WangX, et al.Enhanced immune responses of mice inoculated recombinant adenoviruses expressing GP5 by fusion with GP3 and/or GP4 of PRRS virus. Virus Res, 2008; 136:50–57.
14.
JiangY, ShangH, XuH, et al.Simultaneous detection of porcine circovirus type 2, classical swine fever virus, porcine parvovirus and porcine reproductive and respiratory syndrome virus in pigs by multiplex polymerase chain reaction. Vet J, 2010; 183:172–175.
15.
KimmanTG, CornelissenLA, MoormannRJ, et al.Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. Vaccine, 2009; 27:3704–3718.
16.
LabarqueG, Van GuchtS, Van ReethK, et al.Respiratory tract protection upon challenge of pigs vaccinated with attenuated porcine reproductive and respiratory syndrome virus vaccines. Vet Microbiol, 2003; 95:187–197.
17.
Le BonA, SchiavoniG, D'AgostinoG, et al.Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity, 2001; 14:461–470.
18.
LiJ, JiangP, LiY, et al.HSP70 fused with GP3 and GP5 of porcine reproductive and respiratory syndrome virus enhanced the immune responses and protective efficacy against virulent PRRSV challenge in pigs. Vaccine, 2009; 27:825–832.
19.
LinY, QigaiH, XiaolanY, et al.The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs. Vaccine, 2005; 23:4436–4441.
20.
LinghuaZ, XingshanT, and FengzhenZ. In vivo immunostimulatory effects of CpG ODN in newborn piglets. Mol Immunol, 2007; 44:1238–1244.
21.
MartelliP, GozioS, FerrariL, et al.Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: clinical protection and cell-mediated immunity. Vaccine, 2009; 27:3788–3799.
22.
MateuE, and DiazI. The challenge of PRRS immunology. Vet J, 2008; 177:345–351.
23.
MeierWA, GaleotaJ, OsorioFA, et al.Gradual development of the interferon-gamma response of swine to porcine reproductive and respiratory syndrome virus infection or vaccination. Virology, 2003; 309:18–31.
24.
MeierWA, HusmannRJ, SchnitzleinWM, et al.Cytokines and synthetic double-stranded RNA augment the T helper 1 immune response of swine to porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol, 2004; 102:299–314.
25.
MosmannT. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983; 65:55–63.
26.
MurtaughMP, XiaoZ, and ZuckermannF. Immunological responses of swine to porcine reproductive and respiratory syndrome virus infection. Viral Immunol, 2002; 15:533–547.
27.
NilubolD, PlattKB, HalburPG, et al.The effect of a killed porcine reproductive and respiratory syndrome virus (PRRSV) vaccine treatment on virus shedding in previously PRRSV infected pigs. Vet Microbiol, 2004; 102:11–18.
28.
PapatsirosVG, AlexopoulosC, KritasSK, et al.Long-term administration of a commercial porcine reproductive and respiratory syndrome virus (PRRSV)-inactivated vaccine in PRRSV-endemically infected sows. J Vet Med B Infect Dis Vet Public Health, 2006; 53:266–272.
29.
PirasF, BollardS, LavalF, et al.Porcine reproductive and respiratory syndrome (PRRS) virus-specific interferon-gamma(+) T-cell responses after PRRS virus infection or vaccination with an inactivated PRRS vaccine. Viral Immunol, 2005; 18:381–389.
30.
ProiettiE, BracciL, PuzelliS, et al.Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol, 2002; 169:375–383.
31.
QuanZ, QinZG, ZhenW, et al.Plasmid containing CpG oligodeoxynucleotides can augment the immune responses of pigs immunized with porcine reproductive and respiratory syndrome killed virus vaccine. Vet Immunol Immunopathol, 2010; 136:257–264.
32.
ReedLJ, and MuenchH. A simple method of estimating fifty percent endpoints. Am J Epidemiol, 1938; 27:493–497.
33.
RoyaeeAR, HusmannRJ, DawsonHD, et al.Deciphering the involvement of innate immune factors in the development of the host response to PRRSV vaccination. Vet Immunol Immunopathol, 2004; 102:199–216.
34.
ScorttiM, PrietoC, AlvarezE, et al.Failure of an inactivated vaccine against porcine reproductive and respiratory syndrome to protect gilts against a heterologous challenge with PRRSV. Vet Rec, 2007; 161:809–813.
35.
ToveyMG, LallemandC, MeritetJF, et al.Adjuvant activity of interferon alpha: mechanism(s) of action. Vaccine, 2006; 24Suppl 2:S2-46-47.
36.
VanheeM, DelputtePL, DelrueI, et al.Development of an experimental inactivated PRRSV vaccine that induces virus-neutralizing antibodies. Vet Res, 2009; 40:63.
37.
WangT, FangL, ZhaoF, et al.Exosomes mediate intercellular transmission of porcine reproductive and respiratory syndrome virus. J Virol, 2018; 92:pii: e01734-17.
38.
WangX, LiJ, JiangP, et al.GM-CSF fused with GP3 and GP5 of porcine reproductive and respiratory syndrome virus increased the immune responses and protective efficacy against virulent PRRSV challenge. Virus Res, 2009; 143:24–32.
39.
XueQ, ZhaoYG, ZhouYJ, et al.Immune responses of swine following DNA immunization with plasmids encoding porcine reproductive and respiratory syndrome virus ORFs 5 and 7, and porcine IL-2 and IFNgamma. Vet Immunol Immunopathol, 2004; 102:291–298.
40.
ZhaoJ, YuHY, GanL, et al.Soluble expression, protein purification and quality control of recombinant porcine interferon-alpha. Kafkas Univ Vet Fak Derg, 2017; 23:825–829.
41.
ZuckermannFA, GarciaEA, LuqueID, et al.Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge. Vet Microbiol, 2007; 123:69–85.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
